Juan-Carlos Murciano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4738519/publications.pdf

Version: 2024-02-01

279487 454577 1,747 32 23 30 citations g-index h-index papers 32 32 32 1660 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pro-thrombotic State Induced by Post-translational Modification of Fibrinogen by Reactive Nitrogen Species. Journal of Biological Chemistry, 2004, 279, 8820-8826.	1.6	201
2	Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nature Biotechnology, 2003, 21, 891-896.	9.4	168
3	Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. American Journal of Physiology - Cell Physiology, 2003, 285, C1339-C1347.	2.1	142
4	ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood, 2003, 101, 3977-3984.	0.6	107
5	Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood, 2010, 115, 5241-5248.	0.6	87
6	Cerebrovascular Thromboprophylaxis in Mice by Erythrocyte-Coupled Tissue-Type Plasminogen Activator. Circulation, 2008, 118, 1442-1449.	1.6	77
7	Blood Clearance and Activity of Erythrocyte-Coupled Fibrinolytics. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 1106-1113.	1.3	71
8	Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood, 2003, 102, 926-933.	0.6	64
9	Platelet-Endothelial Cell Adhesion Molecule-1-Directed Immunotargeting to Cardiopulmonary Vasculature. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 777-786.	1.3	61
10	Human complement receptor type 1–directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood, 2006, 108, 1895-1902.	0.6	60
11	Mouse Model of Microembolic Stroke and Reperfusion. Stroke, 2004, 35, 2177-2182.	1.0	59
12	Cellâ€selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting. FASEB Journal, 2001, 15, 416-426.	0.2	57
13	Regulation of the Complement-Mediated Elimination of Red Blood Cells Modified with Biotin and Streptavidin. Analytical Biochemistry, 1996, 241, 109-119.	1.1	55
14	Vascular Immunotargeting of Glucose Oxidase to the Endothelial Antigens Induces Distinct Forms of Oxidant Acute Lung Injury. American Journal of Pathology, 2002, 160, 1155-1169.	1.9	55
15	Urokinase mediates fibrinolysis in the pulmonary microvasculature. Blood, 2000, 96, 1820-1826.	0.6	54
16	Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. Journal of Controlled Release, 2009, 139, 190-196.	4.8	52
17	Targeting of a Mutant Plasminogen Activator to Circulating Red Blood Cells for Prophylactic Fibrinolysis. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 1022-1031.	1.3	51
18	Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood, 2008, 111, 1999-2006.	0.6	46

#	Article	IF	Citations
19	The Glycocalyx Protects Erythrocyte-Bound Tissue-Type Plasminogen Activator from Enzymatic Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 158-164.	1.3	44
20	Dissociation between alveolar transmigration of neutrophils and lung injury in hyperoxia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 291, L1050-L1058.	1.3	43
21	Platelets inhibit the lysis of pulmonary microemboli. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 282, L529-L539.	1.3	32
22	Fibrin Affinity of Erythrocyte-Coupled Tissue-Type Plasminogen Activators Endures Hemodynamic Forces and Enhances Fibrinolysis in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1130-1136.	1.3	32
23	Vascular Immunotargeting to Endothelial Surface in a Specific Macrodomain in Alveolar Capillaries. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1295-1302.	2.5	30
24	Characterization of Endothelial Internalization and Targeting of Antibody–Enzyme Conjugates in Cell Cultures and in Laboratory Animals. , 2004, 283, 021-036.		25
25	In Vivo Survival and Organ Uptake of Loaded Carrier Rat Erythrocytes. Journal of Biochemistry, 1996, 120, 286-291.	0.9	24
26	tPA regulates pulmonary vascular activity through NMDA receptors. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 301, L307-L314.	1.3	19
27	In vitro properties and organ uptake of rat band 3 cross-linked erythrocytes. Biochimie, 1997, 79, 53-61.	1.3	13
28	Clot penetration and retention by plasminogen activators promote fibrinolysis. Biochemical Pharmacology, 2013, 85, 216-222.	2.0	12
29	Coupling of anti-thrombotic agents to red blood cells offers safer and more effective management of thrombosis. Discovery Medicine, 2003, 3, 28-9.	0.5	3
30	Urokinase mediates fibrinolysis in the pulmonary microvasculature. Blood, 2000, 96, 1820-1826.	0.6	2
31	Influence of Aerobic Oxidation of Mouse Erythrocytes on their Recognition by Macrophages. Bioscience Reports, 2000, 20, 157-166.	1.1	1
32	New Murine Sub-massive Pulmonary Embolism Model, Sensitive To Both Clinical Treatments And Diagnostic Techniques. , 2010, , .		0